In addition, patients diagnosed with insulin resistance syndrome, also called metabolic syndrome, characterised by hyperinsulinemia and chronic inflammation, are at greater risk for malignancies.42 Together, these considerations suggest that an angiostatic INSR targeting approach may constitute a valid anti-cancer strategy in the clinic. Here, INSR is linked to hyperinsulinism.